PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery
Watch On Demand
In this webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments.
Johnson is joined during the Q&A by Rachel Mendes, Senior Director of Business Development & Strategy at Beantown Biotech.
Beantown Biotech is a contract research organisation specialising in drug discovery services with extensive expertise in assay development and screening technologies. Johnson will present the company’s successful implementation of TPD strategies.
Attendees will learn:
- How TPD offers a novel therapeutic approach for previously undruggable targets in cancer pathways.
- The critical role of CDK2 in cell cycle regulation and its significance in oncology research.
- Through a comprehensive case study, the company will demonstrate various no-wash high-throughput assay methodologies for quantifying CDK2 degradation and evaluating TPD efficacy.
